SAN Sanofi

Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents

Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents



 

COMBINED GENERAL MEETING OF APRIL 29, 2026

AVAILABILITY OF PREPARATORY DOCUMENTS

The Company’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday April 29, 2026 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris.

The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the website of the Bulletin des Annonces Légales ObligatoiresBALO” () on Friday March 13, 2026, bulletin n°31.

The notice of meeting (avis de convocation) was published on the website of the Bulletin des Annonces Légales ObligatoiresBALO” () on this day, Wednesday April 8, 2026.

The preparatory documents for this meeting will be made available to the shareholders in accordance with the applicable legal and regulatory provisions.

For registered shareholders, you will receive your notice of the General Meeting directly by post or by 

e-mail, depending on your choice. To request additional documents, you must complete the document request form on page 62 of the notice of meeting and return it to Uptevia, Assemblées Générales – 90-110 esplanade du Général de Gaulle – 92931 Paris La Défense CEDEX, no later than Saturday April 25, 2026.

For bearer shareholders, you should contact your financial intermediary.

In accordance with Article R. 22-10-23 of the French Commercial Code, the preparatory documents for this meeting are available on the Company’s website: .

We invite you to regularly consult the “Annual General Meetings” section of our website, which will be updated with any changes regarding the participation in the meeting.

* * *

Attachment



EN
08/04/2026

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Sanofi - Combined General Meeting of April 29, 2026 - Availability of ...

Sanofi - Combined General Meeting of April 29, 2026 - Availability of Preparatory documents   COMBINED GENERAL MEETING OF APRIL 29, 2026 AVAILABILITY OF PREPARATORY DOCUMENTS The Company’s shareholders are invited to attend the Combined General Meeting to be held on Wednesday April 29, 2026 at 2:30 p.m. (CET) at the Palais des Congrès – Amphithéâtre Bleu – 2, place de la Porte Maillot – 75017 Paris. The notice of meeting (avis de réunion), including the agenda and the draft resolutions as well as the terms and conditions for participating and voting in the meeting, was published on the ...

 PRESS RELEASE

Sanofi - Assemblée Générale Mixte du 29 avril 2026 - Mise à dispositio...

Sanofi - Assemblée Générale Mixte du 29 avril 2026 - Mise à disposition des documents préparatoires ASSEMBLÉE GÉNÉRALE MIXTE DU 29 AVRIL 2026 MODALITÉS DE MISE À DISPOSITION OU DE CONSULTATION DES DOCUMENTS PRÉPARATOIRES Les actionnaires de la Société sont invités à participer à l’assemblée générale mixte qui se tiendra le mercredi 29 avril 2026 à 14 h 30 au Palais des Congrès – Amphithéâtre Bleu - 2, place de la Porte Maillot – 75017 Paris. L’avis de réunion, comportant l’ordre du jour et les projets de résolutions ainsi que les conditions et modalités de participation et de vote à l’as...

 PRESS RELEASE

Press Release: Sanofi’s lunsekimig met primary and key secondary endp...

Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP  The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate-to-severe asthma regardless of biomarker status  The DUET phase 2a study met its primary and key secondary endpoints in chronic rhinosinusitis with nasal polyps, reinforcing lunsekimig’s potential as a respiratory treatmentThe exploratory VELVET phase 2b study did ...

 PRESS RELEASE

Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d...

Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale L’étude de phase 2b AIRCULES a atteint son critère d’évaluation principal et ses critères d’évaluation secondaires clés dans l’asthme modéré à sévère, quel que soit le statut des bio...

 PRESS RELEASE

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic g...

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The European Commission has granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight o...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch